The DSM-5 classifies substance use disorders across five primary categories. Substance addiction disorder covers conditions where compulsive use continues despite negative consequences to health, relationships, and daily functioning.
Each category has distinct biological effects, withdrawal patterns, and treatment requirements. Knowing the differences matters because treatment approaches vary significantly between substance types and getting the wrong treatment for the wrong disorder produces poor outcomes.
1. Alcohol Use Disorder
Alcohol use disorder is the most prevalent substance use disorder in the United States. It involves a pattern of drinking that produces significant impairment across at least two of eleven DSM-5 criteria within a twelve-month period.
How It Affects the Brain
Alcohol enhances GABA inhibition and suppresses glutamate activity. The brain compensates by downregulating GABA and upregulating glutamate over time. When alcohol is removed, the excitatory system activates without suppression. This causes withdrawal symptoms ranging from tremors and anxiety to seizures and delirium tremens in severe cases.
Severity Levels
- Mild: 2 to 3 DSM-5 criteria met
- Moderate: 4 to 5 criteria met
- Severe: 6 or more criteria met
Treatment Approach
Medically supervised withdrawal is the essential first step for moderate to severe presentations. FDA-approved medications including naltrexone, acamprosate, and disulfiram reduce cravings and relapse risk at different stages of recovery. Behavioral therapy addresses the compulsive use pattern and the psychological triggers that sustain it long term.
2. Stimulant Use Disorder
Stimulant use disorder involves compulsive use of substances that flood the brain’s reward system with dopamine. The intense euphoria produced is followed by a sharp depletion crash that drives repeated use.
How It Affects the Brain
Repeated dopamine surges reduce receptor density in the nucleus accumbens over time. This creates anhedonia, where the person loses the ability to feel pleasure from everyday activities without the substance. The brain becomes dependent on the stimulant to reach baseline dopamine function.
Substances in This Category
Cocaine, methamphetamine, and misused prescription stimulants such as amphetamine salts all fall here. Methamphetamine causes the most severe dopaminergic damage. Neuroimaging studies show receptor recovery taking up to two years of sustained abstinence in heavy methamphetamine users.
Treatment Approach
No FDA-approved medications exist specifically for stimulant use disorder. Contingency management, which uses structured positive reinforcement for verified abstinence, currently shows the strongest clinical outcomes. CBT is used alongside it to address the thought patterns and behavioral triggers that sustain use.
3. Opioid Use Disorder
Opioid use disorder involves compulsive use of substances that bind to mu-opioid receptors in the brain and spinal cord. It carries the highest overdose mortality risk of all substance use disorder categories.
How It Affects the Brain
Opioids produce analgesia and euphoria by releasing dopamine in the reward circuit and suppressing pain signaling throughout the central nervous system. Physical dependence develops rapidly with regular use. The brain’s natural endorphin production shuts down as it becomes reliant on the external substance.
Substances in This Category
Prescription opioids, heroin, and illicitly manufactured fentanyl all fall within this category. Fentanyl is approximately 100 times more potent than morphine. Its prevalence in the illicit drug supply has contributed significantly to overdose mortality in recent years.
Treatment Approach
Opioid use disorder has the strongest evidence base for medication-assisted treatment of any substance addiction disorder. The National Institute on Drug Abuse confirms that buprenorphine, methadone, and naltrexone are all FDA-approved and reduce overdose mortality significantly when used consistently. Withdrawal produces severe flu-like symptoms, muscle cramps, insomnia, and intense cravings that are a primary driver of relapse without medical support.
4. Cannabis Use Disorder
Cannabis use disorder is frequently underestimated due to the widespread belief that cannabis carries no addiction risk. Clinical data shows otherwise.
How It Affects the Brain
Cannabis acts on CB1 receptors that regulate mood, appetite, memory, and pain. Chronic heavy use downregulates CB1 receptor density and disrupts baseline endocannabinoid function. The person develops tolerance and requires increasing amounts to achieve the same effect. When use stops, the disrupted endocannabinoid system produces withdrawal symptoms.
Who Is Most at Risk
Around 9% of people who use cannabis develop dependence. This rises to 17% among those who begin use during adolescence when the endocannabinoid system is still developing. Early-onset use is also associated with higher rates of co-occurring anxiety and depression.
Withdrawal and Treatment
Withdrawal symptoms include irritability, mood instability, sleep disruption, decreased appetite, and cravings lasting two to three weeks after cessation. These symptoms are a significant relapse trigger without structured clinical support. CBT and motivational enhancement therapy are the most effective treatment approaches currently available for this disorder category. No FDA-approved medications exist specifically for cannabis use disorder at this time.
5. Sedative, Hypnotic, and Anxiolytic Use Disorder
This category covers misuse of central nervous system depressants that act on the GABA receptor system. It includes some of the most commonly prescribed medications in outpatient psychiatric care.
How It Affects the Brain
Benzodiazepines such as alprazolam, diazepam, and clonazepam enhance GABA activity the same way alcohol does. The brain adapts by downregulating GABA receptors. Dependence can develop within weeks of regular use, even at prescribed therapeutic doses. When the substance is removed, the excitatory rebound produces severe withdrawal.
Why Withdrawal Is Medically Serious
Benzodiazepine and barbiturate withdrawal can produce seizures and cardiovascular instability. Abrupt cessation without medical oversight carries genuine life-threatening risk. This makes sedative withdrawal one of the most medically serious of all substance use disorder categories. Supervised tapering using a long-acting benzodiazepine is the clinical standard for safe discontinuation.
Treatment Approach
After medical stabilization through supervised tapering, CBT targeting the underlying anxiety that drove the original use is the primary therapeutic approach. Co-occurring anxiety disorders are present in the majority of people in this category and must be addressed alongside the substance use disorder to prevent relapse.
Why Co-Occurring Conditions Matter
Substance use disorders rarely exist alone. Depression, anxiety, PTSD, and ADHD all increase the risk of developing a substance use disorder and worsen outcomes when left unaddressed alongside it.
Each condition creates a bidirectional relationship with substance use. Anxiety drives benzodiazepine and alcohol misuse. Depression deepens stimulant and opioid use as self-medication. PTSD is present in a significant proportion of people with opioid use disorder. Treating substance use without addressing the underlying psychiatric condition produces high relapse rates regardless of the treatment quality.
Integrated psychiatric evaluation that screens for both substance use and co-occurring mental health conditions is the clinical standard for effective long-term care.
Start With an Accurate Assessment
Misidentifying the substance type or missing a co-occurring condition derails treatment from the start. Each of the five disorder categories requires a different clinical approach. A thorough psychiatric evaluation is the only way to build a plan that addresses the specific presentation accurately.
Cervello-Wellness provides psychiatric evaluation and structured care planning for the full range of substance use disorders across Alexandria, VA. Our team at 2800 Eisenhower Avenue, Suite 220 D-8 assesses the complete clinical picture before any treatment plan is built. Call (301) 392-7120 to schedule your evaluation today.
